Thermo Fisher Scientific: Mark Stevenson, Syed Jafry, Michel Lagarde, Gianluca Pettiti
Thermo Fisher Scientific announced that executive vice president and chief operating office Mark Stevenson has notified the company of his decision to retire, effective March 18, 2022. In addition, Syed Jafry, senior VP of regions, has notified the company of his decision to retire effective March 31, 2022.
Thermo Fisher's board has also appointed Michel Lagarde, who currently serves as executive VP, to serve as executive VP and COO, effective Jan. 1, 2022. Lagarde was appointed executive VP in September 2019 and was president of the company's pharma services business from August 2017 until September 2019. He previously served as president of Patheon from May 2016 to May 2017 and as president and COO from May 2017 until its acquisition by Thermo Fisher in August 2017.
Additionally, the company's board has appointed Gianluca Pettiti as executive VP, effective Dec. 27. Pettiti is currently serving as senior VP and president of the company's specialty diagnostics business. He previously served as president of the firm's biosciences business from January 2018 to October 2019 and led Thermo Fisher's business in China from January 2015 to December 2017.
Sera Prognostics: Paul Kearney
Sera Prognostics has appointed Paul Kearney its chief data officer, effective Oct. 1. He will help direct, manage, and analyze Sera's scientific and business datasets. Kearney has cofounded several biotech companies and data enterprises and previously held positions at the Institute for Systems Biology; Integrated Diagnostics; Caprion, now called CellCarta; Data Incites; Bioinformatics Solutions; and AllerGenis.
PreludeDx: Karuna Mittal
PreludeDx has appointed Karuna Mittal as director of research and development. Mittal's most recent research efforts were at Emory University School of Medicine where she investigated novel targeted cancer therapies using functional genomics. Her research expertise extends to a variety of oncology areas including biomarker and targeted therapy discovery in breast, prostate, ovarian, and head and neck cancer.
For additional recent items on executive appointments and promotions in omics and molecular diagnostics, please see the People in the News page on our website.